Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
filingDate |
2009-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_960b46371a8b88334e216a4a968eeedb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c78543f25aa939a9d7aab6da33cb3a2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83ace451ea596ccecb95152efc5ed9ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d630df8e0978f99858e02c7a12f6d25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1953ea41bebcee5552afb26eac68d711 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cce02eb3d9fa99ec969023eb3c67da5 |
publicationDate |
2011-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20110093923-A |
titleOfInvention |
2,5-diamino-substituted pyrido [4,3-D] pyrimidines as autotaxin inhibitors for cancer |
abstract |
The present invention relates to pyridopyrimidine derivatives according to formula (I) as autotaxin inhibitors and in particular physiologically induced and mediated and / or propagated by increased lysophosphatidic acid levels and / or activation of autotaxin in different cancers And / or the use of said compound for the treatment and / or prevention of pathophysiological conditions: . |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20220137343-A |
priorityDate |
2008-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |